Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Gland Pharma
GLAND
Gland Pharma
Rapid GLP-1 Capacity Increase Will Erode Profit Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 12 Analysts
Published
06 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹1,243.27
56.3% overvalued
intrinsic discount
16 Aug
₹1,943.60
Loading
1Y
0.7%
7D
-0.3%
Author's Valuation
₹1.2k
56.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹1.2k
56.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
85b
2017
2019
2021
2023
2025
2027
2028
Revenue ₹85.1b
Earnings ₹14.9b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
13.21%
Pharma revenue growth rate
0.55%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹14.89b
Earnings '28
x
19.61x
PE Ratio '28
=
₹292.08b
Market Cap '28
₹292.08b
Market Cap '28
/
164.91m
No. shares '28
=
₹1.77k
Share Price '28
₹1.77k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹1.24k
Fair Value '25